<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153149</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTRSC02-003</org_study_id>
    <secondary_id>2019-003153-28</secondary_id>
    <nct_id>NCT04153149</nct_id>
  </id_info>
  <brief_title>HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy</brief_title>
  <official_title>HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of vutrisiran 25 mg administered
      subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR
      amyloidosis with cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits)</measure>
    <time_frame>30-36 months</time_frame>
    <description>All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 6-Minute Walk Test (6-MWT) at Month 30</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) at Month 30</measure>
    <time_frame>Baseline, Month 30</time_frame>
    <description>The KCCQ is a 23-item self-administered questionnaire quantifying 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS]). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Left Ventricular (LV) Wall Thickness by Echocardiographic Assessment at Month 30</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Global Longitudinal Strain by Echocardiographic Assessment at Month 30</measure>
    <time_frame>Baseline and Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All-Cause Mortality and Recurrent All-cause Hospitalizations and Urgent HF Visits</measure>
    <time_frame>30-36 months</time_frame>
    <description>All-cause mortality and recurrent all-cause hospitalizations and urgent HF visits will be compared between treatment groups using an Andersen-Gill model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>30-36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)</measure>
    <time_frame>30-36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in N-terminal prohormone B-type Natriuretic Peptide (NTproBNP) at Month 30</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Transthyretin Amyloidosis (ATTR) With Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Vutrisiran 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo during the double-blind period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vutrisiran</intervention_name>
    <description>Vutrisiran 25 mg will be administered by SC injection q3M.</description>
    <arm_group_label>Vutrisiran 25 mg</arm_group_label>
    <other_name>ALN-TTRSC02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Sterile normal saline (0.9% NaCl) will be administered by SC injection q3M.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a documented diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy,
             classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy or
             wild-type ATTR (wtATTR) amyloidosis with cardiomyopathy meeting pre-specified
             diagnostic criteria

          -  Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF
             OR clinical evidence of HF

        Exclusion Criteria:

          -  Has known primary amyloidosis or leptomeningeal amyloidosis

          -  Has New York Heart Association (NYHA) Class IV heart failure

          -  Has NYHA Class III heart failure AND is at high risk based on pre-specified criteria

          -  Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Screening visit

          -  Has estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m^2

          -  Has received prior TTR-lowering treatment

          -  Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to
             valvular heart disease, or cardiomyopathy due to ischemic heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-ALNYLAM</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-256-9526</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Latvia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ATTR</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>TTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>TTR-mediated amyloidosis</keyword>
  <keyword>Amyloidosis, Hereditary</keyword>
  <keyword>Amyloidosis, Hereditary, Transthyretin-Related</keyword>
  <keyword>Familial Amyloidosis</keyword>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Transthyretin amyloid cardiomyopathy</keyword>
  <keyword>TTR cardiomyopathy</keyword>
  <keyword>ATTR-CM</keyword>
  <keyword>Wild-type TTR</keyword>
  <keyword>V122I</keyword>
  <keyword>TTR amyloidosis</keyword>
  <keyword>Amyloidosis, Wild Type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

